Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma
Year: 2026
Type: article
Abstract: This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, a phase 3 trial showed that the BCMA‐targeting bispecific antibody teclistamab significantly improved progression‐free survival and overall survival in patients with relapsed or refractory multiple myeloma who received one to three previous lines of therapy. In addition, adjuvant nivolumab fails to improve disease‐free survival in patients with resected NSCLC, and perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer.
Source: Cancer
DOI: 10.1002/cncr.70639
Author: Leah Lawrence
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7233273336
